Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment

Journal of Surgical Oncology

Volumn 101, Issue 6, 2010, Pages 465-470

  Grabellus, Florian ^a   Sheu, Sien Yi ^a   Tötsch, Martin ^a   Lehmann, Nils ^a   Kaiser, Gernot M ^a   Jasani, Bharat ^b   Taeger, Georg ^a   Schmid, Kurt W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Isolated limb perfusion; Melphalan; Metallothionein; Sarcoma; TNF

Indexed keywords

KI 67 ANTIGEN; MELPHALAN; METALLOTHIONEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BONE BIOPSY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER TISSUE; CHONDROSARCOMA; CLEAR CELL SARCOMA; CLINICAL ARTICLE; DRUG RESPONSE; EPITHELIOID SARCOMA; EWING SARCOMA; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYPERTHERMIC ISOLATED LIMB PERFUSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NERVE SHEATH TUMOR; OSTEOSARCOMA; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TISSUE SECTION; TUMOR BIOPSY; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELPHALAN; METALLOTHIONEIN; MIDDLE AGED; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950849840     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21513     Document Type: Article

References (39)

1. Nascimento AG: World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
2. Cormier JN, Pollock RE: Soft tissue sarcomas. CA Cancer J Clin 2004;54:94-109.
3. Grunhagen DJ, de Wilt JH, ten Hagen TL, et al.: Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006;3:94-103.
4. Taeger G, Grabellus F, Podleska LE, et al.: Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperther 2008;24: 193-203. (Pubitemid 351517154)
5. Coyle P, Philcox JC, Carey LC, et al.: Metallothionein: The multipurpose protein. Cell Mol Life Sci 2002;59:627-647.
6. Theocharis SE, Margeli AP, Klijanienko JT, et al.: Metallothionein expression in human neoplasia. Histopathology 2004; 45:103-118.
7. Dziegiel P, Suder E, Surowiak P, et al.: Expression of metallothionein in synovial sarcoma cells. Appl Immunohistochem Mol Morphol 2002;10:357-362. (Pubitemid 35453696)
8. Dziegiel P, Salwa-Zurawska W, Zurawski J, et al.: Prognostic significance of augmented metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol 2005;20:83-89. (Pubitemid 40028986)
9. Uozaki H, Horiuchi H, Ishida T, et al.: Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 1997;79:2336-2344. (Pubitemid 27251016)
10. Cherian MG, Howell SB, Imura N, et al.: Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol 1994;126:1-5.
11. Lazo JS, Pitt BR: Metallothioneins and cell death by anticancer drugs. Annu Rev Pharmacol Toxicol 1995;35:635-653.
12. Cai L, Satoh M, Tohyama C, et al.: Metallothionein in radiation exposure: Its induction and protective role. Toxicology 1999;132: 85-98. (Pubitemid 29121947)
13. Yap X, Tan HY, Huang J, et al.: Over-expression of metallothionein predicts chemoresistance in breast cancer. J Pathol 2009;217:563-570.
14. Okazaki Y, Miura N, Satoh M, et al.: Metallothionein-mediated resistance to multiple drugs can be induced by several anticancer drugs in mice. Biochem Biophys Res Commun 1998;245:815-818. (Pubitemid 28414000)
15. Satoh M, Cherian MG, Imura N, et al.: Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 1994;54:5255-5257. (Pubitemid 24336008)
16. Padussis JC, Steerman SN, Tyler DS, et al.: Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI. Int J Hyperther 2008;24:239-249.
17. Eggermont AM, Schraffordt KH, Klausner JM, et al.: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-764.
18. Jasani B, Schmid KW: Significance of metallothionein overexpression in human tumours. Histopathology 1997;31:211-214. (Pubitemid 27397912)
19. Abdel-Mageed A, Agrawal KC: Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 1997;4:199-207. (Pubitemid 127667116)
20. Bianchi A, Becuwe P, Collet P, et al.: Clofibric acid downregulation of metallothionein IIA in HepG2 human hepatoma cells. Biochem Pharmacol 2002;63:237-245. (Pubitemid 34158824)
21. Bakka A, Endresen L, Johnsen AB, et al.: Resistance against cisdichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol Appl Pharmacol 1981;61:215-226. (Pubitemid 12201470)
22. Komdeur R, Plaat BE, Hoekstra HJ, et al.: Expression of Pglycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer 2001;91:1940-1948. (Pubitemid 32424122)
23. Stein U, Jurchott K, Schlafke M, et al.: Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. J Clin Oncol 2002;20:3282-3292. (Pubitemid 34831527)
24. Perez-Gutierrez S, Gonzalez-Campora R, Amerigo-Navarro J, et al.: Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications. Pathol Oncol Res 2007;13:203-208. (Pubitemid 350221222)
25. Gaumann A, Tews DS, Mentzel T, et al.: Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin. Virchows Arch 2003;442:529-537. (Pubitemid 36819246)
26. Raaijmakers HG, Izquierdo MA, Lokhorst HM, et al.: Lung-resistance- related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998;91: 1029-1036.
27. Kondo Y, Woo ES, Michalska AE, et al.: Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res 1995;55:2021-2023.
28. Hadama T, Kinoshita M, Kobayashi D, et al.: Endogenous tumor necrosis factor promotes resistance to cellular stresses by inducing the metallothionein-1A gene. Anticancer Res 2002;22: 4059-4063. (Pubitemid 36134434)
29. Sato M, Sasaki M, Hojo H: Tissue specific induction of metallothionein synthesis by tumor necrosis factor-alpha. Res Commun Chem Pathol Pharmacol 1992;75:159-172.
30. Sciavolino PJ, Vilcek J: Regulation of metallothionein gene expression by TNF-alpha and IFN-beta in human fibroblasts. Cytokine 1995;7:242-250.
31. Cherian MG, Apostolova MD: Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol (Noisy-le-grand) 2000;46:347-356.
32. Deng DX, Chakrabarti S, Waalkes MP, et al.: Metallothionein and apoptosis in primary human hepatocellular carcinoma and metastatic adenocarcinoma. Histopathology 1998;32:340-347. (Pubitemid 28186593)
33. Kondo Y, Rusnak JM, Hoyt DG, et al.: Enhanced apoptosis in metallothionein null cells. Mol Pharmacol 1997;52:195-201. (Pubitemid 27349610)
34. Oyama T, Take H, Hikino T, et al.: Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 1996; 53:112-117. (Pubitemid 26087918)
35. Zelger B, Hittmair A, Schir M, et al.: Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology 1993;23:257-263. (Pubitemid 23281927)
36. Schmid KW, Ellis IO, Gee JM, et al.: Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat Histopathol 1993;422: 153-159.
37. Poulsen CB, Borup R, Borregaard N, et al.: Prognostic significance of metallothionein in B-cell lymphomas. Blood 2006;108:3514-3519.
38. Weinlich G, Eisendle K, Hassler E, et al.: Metallothionein - overexpression as a highly significant prognostic factor in melanoma: A prospective study on 1270 patients. Br J Cancer 2006;94:835-841.
39. Shnyder SD, Hayes AJ, Pringle J, et al.: P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. Br J Cancer 1998;78:757-759. (Pubitemid 28418308)